Similar to the study by Shoda et al., it also could suggest that the monitoring of HER2 status by ddPCR could offer an insight to predict tumor progression and evaluate treatment efficacy in the clinical courses of GC patients. This evidence concerns the gene ERBB2 and gastric cancer.